A STUDY OF VELCADE (BORTEZOMIB) MELPHALAN-PREDNISONE (VMP) COMPARED TO DARATUMUMAB IN COMBINATION WITH VMP (D-VMP), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR HIGH-DOSE THERAPY (ASIA PACIFIC REGION):